Navigation Links
CTI Reports Final Results from Cooperative Group and NCI-Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
Date:6/1/2013

CHICAGO and SEATTLE, June 1, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported on final results from a cooperative group and NCI-sponsored Phase 2 clinical trial of brostallicin in combination with cisplatin for the treatment of women with metastatic triple-negative breast cancer (mTNBC). Triple-negative breast cancer lacks progesterone and estrogen receptors and the HER2 biomarker that is present in most breast cancers, which makes standard therapy with hormone or targeted therapy ineffective. The rationale for the present study in TNBC is based on data the demonstrating that silencing of the breast cancer susceptibility gene(s) (BRCA) is associated with substantially enhanced sensitivity to brostallicin.  BRCA is silenced or mutated in most patients with TNBC. In this study of 48 patients with heavily pretreated mTNBC, the 3-month progression free survival (PFS) was 51 percent with 10 confirmed responses (one complete response and nine partial responses). Among the 25 patients who received a reduced brostallicin dose, the overall response rate (ORR) was 28 percent, with 3-month progression-free survival (PFS) of 61.5 percent and median overall survival (OS) of 11.8 months. The final data are being presented during a poster session at the 2013 American Society for Clinical Oncology (ASCO) Meeting being held May 31 to June 4, 2013 in Chicago, Illinois.

Abstract #1059:  Final clinical results and correlative data from the phase II trial of cisplatin (C) and the novel agent brostallicin (B) in patients with metastatic triple negative breast cancer (mTNBC). Poster session, Saturday, June 1, 1:15 to 5:00 p.m. CDT in S Hall A2.

About the Study

The study enrolled women with confirmed measurable metastatic disease and triple-negative subtype breast cancer. A total of 48 women were enrolled in the study and 47 were evaluable
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com
2. Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy
3. Vermillion Reports First Quarter 2013 Results
4. Dyadic International Reports First Quarter 2013 Financial Results
5. Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
6. Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
7. Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update
8. Vanda Pharmaceuticals Reports First Quarter 2013 Results
9. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
10. Regeneron Reports First Quarter 2013 Financial and Operating Results
11. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
(Date:1/22/2015)... BRUNSWICK , Nueva Jersey , 22 de ... Award for Biomedical Research abre hoy su llamada a ... personas cuya investigación científica ha hecho, o tiene el ... la salud humana. Las nominaciones se aceptarán hasta el ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... has been honored for its commitment to sustainability with inclusion ... Varian is the highest ranked healthcare equipment company among the ... during the World Economic Forum at Davos, Switzerland ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... Components, a leading global provider of distributed and ... participation in the "Drive for Innovation" tour, sponsored ... a "pit stop" during the tour,s recent swing ... its role in powering innovation by companies driving ...
... 2012  Neuralstem, Inc. (NYSE Amex: CUR ) announces ... 14th Annual BIO CEO & Investor Conference 2012 in New ... Garr will present a business overview, and an update on ... and pharmaceutical divisions. (Logo:  http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) ...
... intensive research at the nanoscale is the creation of ... electrical throughput, low cost and easy processing, engineers foresee ... generations of touch-screens, video displays, light-emitting diodes and thin-film ... a major engineering hurdle: In processing, these delicate meshes ...
Cached Biology Technology:Micross Components Hosts Stop on "Drive for Innovation" Tour 2Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012 2Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012 3Stanford engineers weld nanowires with light 2
(Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a market ... appointed Steve Gerber to the new role of ... responsible for leading development of mobile platforms and wearable solutions ... success and innovation in the semiconductor industry to his role ...
(Date:12/24/2014)... launch in December 2014, the 1U™ app has ... to remember their usernames and passwords through replacing the antiquated ... assist people who have struggled to remember usernames and passwords, ... focuses on redefining identity, announced today that it is offering ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... the addition of the "The Global Watermarking ... http://photos.prnewswire.com/prnh/20130307/600769 ... global digital media watermarking and fingerprinting markets. Watermarking ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2
... Atlanta, GA Current research suggests that latent ... The related report by Onyeagocha et al, "Latent cytomegalovirus ... issue of The American Journal of Pathology . ... in the United States. Most people who are ...
... and chemical changes occurring at a remote Arctic lake are ... result of human-caused climate change, according to a new study ... While environmental changes at the lake over the past millennia ... of climate change -- like periodic, well-understood wobbles in Earth,s ...
... Fla. You might not know what it,s called, ... after an accident, it is likely you have received ... patient,s throat to prevent regurgitation and spilling of stomach ... being administered. Such regurgitation could result in serious ...
Cached Biology News:The bowels of infection 2Arctic lake sediments show warming, unique ecological changes in recent decades 2Arctic lake sediments show warming, unique ecological changes in recent decades 3UF scientists discover new explanation for controversial old patient-care technique 2UF scientists discover new explanation for controversial old patient-care technique 3
Agarose, pulse field, 100 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Molecular Biological Resources has extensive abilities cloning and expression of prokaryotic and eukaryotic proteins. Please contact lloconne@molbiores.com to discuss your project. Contact lloconne@...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
quantitation of phosphatase activity, evaluation of hits and leads from HTS...
Biology Products: